Literature DB >> 18460709

Percutaneous coronary intervention in a patient with acute ST-elevation myocardial infarction and hemophilia A.

David Quintero1, Mazda Biria, David G Meyers.   

Abstract

We report the first case of myocardial infarction in a hemophilia patient which was not directly precipitated by infusion of a clotting factor, and the second hemophilia patient with infarction treated with primary coronary artery stenting. Anticoagulation and platelet inhibition are problematic in such patients. At 2 years after infarction, our patient has experienced neither ischemic nor bleeding complications.

Entities:  

Mesh：

Year:  2008        PMID： 18460709

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN： 1042-3931            Impact factor:   2.022


  4 in total

1.  Discrepant ratios of arterial versus venous thrombosis in hemophilia A as compared with hemophilia B.

Authors:  Antonio Girolami; Irene Bertozzi; Giulia Berti de Marinis; Valentina Tasinato; Luisa Sambado
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

2.  Successful percutaneous coronary intervention in a patient with combined deficiency of FV and FVIII due to novel compound heterozygous mutations in LMAN1.

Authors:  A J Patel; H-H Liu; R A Lager; V Malkovska; B Zhang
Journal:  Haemophilia       Date:  2013-04-05       Impact factor: 4.287

Review 3.  Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management.

Authors:  Paul Fefer; Sharon Gannot; Aaron Lubetsky; Uri Martinowitz; Shlomi Matetzky; Victor Guetta; Amit Segev
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 4.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.